Grace Therapeutics (GRCE) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed Werewolf Therapeutics (HOWL) over the past year, losing 32.0% versus a loss of 51.6%. Over five years, GRCE leads with a -80.5% price change compared with -94.7% for HOWL. Werewolf Therapeutics is the larger company by market cap ($44.2 million vs $42.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRCE | HOWL |
|---|---|---|
| Share price | $2.04 | $0.91 |
| Market cap | $42.91M | $44.23M |
| 1-day change | -2.86% | -1.10% |
| YTD return | -41.04% | +43.53% |
| 1-year return | -32.00% | -51.60% |
| 5-year return | -80.46% | -94.67% |
| EPS (TTM) | $-1.17 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.18 | $1.85 |
| 52-week low | $1.79 | $0.27 |
| Distance from 52-week high | -60.62% | -50.81% |
| Analyst consensus | none | none |
| Avg. price target upside | +187.75% | +669.23% |
| Average volume | 169.41K | 6.80M |
| Shares outstanding | 21.04M | 48.60M |
| Employees | 5 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed HOWL by 19.6 percentage points over the past year.
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
GRCE vs HOWL FAQ
Which is bigger, Grace Therapeutics or Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $44.23M compared with $42.91M for Grace Therapeutics (GRCE).
Which stock has performed better over the past year, GRCE or HOWL?
GRCE returned -32.00% over the past 12 months, compared with -51.60% for HOWL (price return, excluding dividends). Past performance does not predict future results.
Are Grace Therapeutics and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.